LT5524B - Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas - Google Patents

Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas Download PDF

Info

Publication number
LT5524B
LT5524B LT2008003A LT2008003A LT5524B LT 5524 B LT5524 B LT 5524B LT 2008003 A LT2008003 A LT 2008003A LT 2008003 A LT2008003 A LT 2008003A LT 5524 B LT5524 B LT 5524B
Authority
LT
Lithuania
Prior art keywords
meldonium
pharmaceutical composition
lamivudine
reverse transcriptase
stavudine
Prior art date
Application number
LT2008003A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2008003A (en
Inventor
Vija Klusha
Sergejs Isajevs
Jolanta Pupure
Juris Rumaks
Valentina Gordjushina
Immanuels Taivans
Ivars Kalvinsh
Original Assignee
Latvian Institute Of Organic Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37442067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT5524(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Latvian Institute Of Organic Synthesis filed Critical Latvian Institute Of Organic Synthesis
Publication of LT2008003A publication Critical patent/LT2008003A/xx
Publication of LT5524B publication Critical patent/LT5524B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LT2008003A 2005-08-15 2008-01-18 Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas LT5524B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-05-95A LV13544B (en) 2005-08-15 2005-08-15 Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium

Publications (2)

Publication Number Publication Date
LT2008003A LT2008003A (en) 2008-07-25
LT5524B true LT5524B (lt) 2008-10-27

Family

ID=37442067

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2008003A LT5524B (lt) 2005-08-15 2008-01-18 Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas

Country Status (17)

Country Link
US (1) US7700576B2 (et)
EP (1) EP1933823B1 (et)
JP (1) JP5027809B2 (et)
CN (1) CN101252925B (et)
AR (1) AR066995A1 (et)
AT (1) ATE493123T1 (et)
DE (1) DE602006019293D1 (et)
EE (1) EE05529B1 (et)
ES (1) ES2361185T3 (et)
HN (1) HN2006029085A (et)
LT (1) LT5524B (et)
LV (1) LV13544B (et)
PE (1) PE20070233A1 (et)
SV (1) SV2007002655A (et)
UA (1) UA90162C2 (et)
UY (1) UY29751A1 (et)
WO (1) WO2007021164A1 (et)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20146015B (en) * 2009-06-25 2014-01-27 Tetra Sia Novel acetylsalicylic acid salts
LV14848B (lv) * 2012-10-25 2015-06-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompoz&imacr;cija trimetilam&imacr;na-N-oks&imacr;da l&imacr;me&ncedil;a pazemin&amacr;&scaron;anai

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481218A (en) 1978-11-27 1984-11-06 Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr 3-(2,2,2-Trimethylhydrazinium)propionate and method for the preparation and use thereof
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
WO1991017159A1 (en) 1990-05-02 1991-11-14 Iaf Biochem International Inc. 1,3-oxathiolane nucleoside analogues
US5130421A (en) 1988-03-24 1992-07-14 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
EP0560275A1 (en) 1992-03-11 1993-09-15 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of L-carnitine for treating carnitine-depleted HIV-seropositive patients

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481218A (en) 1978-11-27 1984-11-06 Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr 3-(2,2,2-Trimethylhydrazinium)propionate and method for the preparation and use thereof
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5130421A (en) 1988-03-24 1992-07-14 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
WO1991017159A1 (en) 1990-05-02 1991-11-14 Iaf Biochem International Inc. 1,3-oxathiolane nucleoside analogues
EP0560275A1 (en) 1992-03-11 1993-09-15 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of L-carnitine for treating carnitine-depleted HIV-seropositive patients

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BROCKLEHURST P, VOLMINK J.: "Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.", COCHRANE DATABASE SYST REV., 2002, pages 003510
LEWIS W. ET AL.: "Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria", J. CLIN. INVEST., 1992, pages 1354 - 1360, XP002963913, DOI: doi:10.1172/JCI115722

Also Published As

Publication number Publication date
AR066995A1 (es) 2009-09-30
EE05529B1 (et) 2012-04-16
UA90162C2 (ru) 2010-04-12
JP2009504731A (ja) 2009-02-05
PE20070233A1 (es) 2007-06-08
JP5027809B2 (ja) 2012-09-19
WO2007021164A1 (en) 2007-02-22
EP1933823B1 (en) 2010-12-29
ATE493123T1 (de) 2011-01-15
CN101252925B (zh) 2012-04-25
ES2361185T3 (es) 2011-06-14
EE200800014A (et) 2008-06-16
HN2006029085A (es) 2007-11-16
LV13544B (en) 2007-05-20
DE602006019293D1 (de) 2011-02-10
CN101252925A (zh) 2008-08-27
LT2008003A (en) 2008-07-25
SV2007002655A (es) 2007-04-12
US7700576B2 (en) 2010-04-20
UY29751A1 (es) 2007-03-30
US20090137522A1 (en) 2009-05-28
EP1933823A1 (en) 2008-06-25

Similar Documents

Publication Publication Date Title
US20020169140A1 (en) Combination therapy for reduction of toxicity of chemotherapeutic agents
US5719132A (en) Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
CN107898790A (zh) 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
KR20080091767A (ko) (테노포비어 및 라미뷰딘과 같은) 뉴클레오티드 역전사효소억제제 및 뉴클레오시드 역전사효소 억제제를 투여 단위의상이한 부분에 포함하는 약제학적 조합물
JP2004517864A (ja) ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
US10369166B2 (en) Pharmaceutical compositions for treating ebola virus disease
EP1272897B1 (en) Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver
Nelson et al. Emtricitabine (FTC) for the treatment of HIV infection
AU2001238124A1 (en) Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver
Margot et al. In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1
LT5524B (lt) Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas
WO2021205437A1 (en) Pharmaceutical compositions for treating corona virus disease
EP0839033B1 (en) Use of l-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral
CA2344172A1 (en) Antiviral combinations
Lemberg et al. Tolerabilities of antiretrovirals in paediatric HIV infection
TWI405569B (zh) 色素沉著症治療用一日二次服用型口服藥製劑
TWI324927B (en) Pharmaceutical composition on basis of reverse transcriptase inhibitor and meldonium
MXPA03005382A (es) Terapia combinada de dapd con un inhibidor de inosino monofosfato dehidrogenasa.
US20140065246A1 (en) Intracellular calcium modulation for cancer treatment
US7745455B2 (en) Zalcitabine (ddC) boosted lamivudine (3TC) compositions for antiretroviral therapy
Blonk Clinical pharmacology of the HIV integrase inhibitor raltegravir: drug-drug interactions and pharmacokinetics
RU106840U1 (ru) Диспергируемая в воде лекарственная таблетка противотуберкулезного действия
KR20230044481A (ko) 감기약 및 항바이러스제
CA2284483A1 (en) Mixtures of at least two reverse transcriptase inhibitors and hydroxycarbamide, in particular for inhibiting retroviral spread

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20140808